Abstract
Hypertension and high serum cholesterol levels are two of the most relevant risk factors for cardiovascular diseases. A combined increase in both risk factors has been reported in a significant proportion of patients with coronary artery disease. Statins are the most widely used drugs to treat hypercholesterolemia, and they interact with blood pressure control in different populations of hypertensive patients. A significant reduction in blood pressure associated with the use of statins has been described in patients with untreated hypertension and in patients treated with antihypertensive drugs, particularly angiotensin converting enzyme inhibitors and calcium channel blockers. The effect of statins on blood pressure control has also been reported in diabetic patients. The mechanisms responsible for the hypotensive effect seem to be largely independent of the effect of statins on lipid profile, and are probably related to their interaction with endothelial function or angiotensin II receptors. The capacity of statins to improve blood pressure control could be a useful consideration for an integrated approach to better prevention of cardiovascular diseases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
American Heart Association: Heart and Stroke Statistical Update. Dallas: American Heart Association; 2000.
Kannel WB: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996, 275:1571–1576.
Neaton JD, Blackburn H, Jacobs D, et al.: Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152:1490–1500.
Alderman MH, Cohen H, Madhavan S: Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999, 33:1130–1134.
Wilson PWF, D’Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847. The paper suggests a simple way to calculate and understand the importance of cumulative cardiovascular risk factors.
The JNC-VI Sub-Committee: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413–2446.
Chalmers J, MacMahon S, Mancia G, et al.: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999, 21:1009–1060.
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel in Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993, 269:3015–3033.
Julius S, Jamerson K, Mejia A, et al.: The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure study. JAMA 1990, 264:354–358.
Borghi C, Bacchelli S, Degli Esposti D, et al.: Pressor and metabolic correlates to long-term development of stable hypertension in borderline hypertensive patients [abstract]. J Hypertens 1997, 15:S111.
Samuelsson O, Wilhelmsen L, Andersson OK, et al.: Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden. JAMA 1987, 258:1768–1776.
Maron DJ, Fazio S, Linton, Mac Rae F: Current perspectives on statin. Circulation 2000, 101:207–213. This paper clearly summarizes the potential preventive and therapeutic role of statins in patients at risk for cardiovascular disease. It describes the importance of the effects of statins not directly related to lipid management.
Simvastatin Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.
Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335(14):1001–1009.
Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349–1357.
Wolozin B, Kelleman W, Rousseau P, et al.: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-metylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439–1443.
Vaughan CJ, Gotto AM, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 1999, 35:1–10.
O’Donnell MP, Kasiske BL, Katz SA, et al.: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 1992, 20:651–658.
Wilson TW, Alonso-Galicia M, Roman RJ: Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998, 31(1 Pt 2):225–231 The paper describes an interesting interaction between the use of statins and changes in renal function. This mechanism could provide a strong rationale for the preventive effect of statins on the development of experimental hypertension.
Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997, 30:968–974.
Clarke SL: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Ann Rev Biochem 1992, 61:355–386.
Goode GK, Miller JP, Heagerty AM: Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995, 345:362–364.
Sung BH, Izzo JL, Wilson MF: Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997, 10:592–599.
Jarai Z, Kapocsi J, Farsang C, et al.: Effect of fluvastatin on serum lipid levels in essential hypertension. Orv Hetil 1996, 137:1857–1859.
Straznicky NE, Howes LG, Lam W, et al.: Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995, 75:582–586.
Abetel G, Poget PN, Bonnabry JP: Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study. Schweiz Med Wochenschr 1998, 128:272–277.
D’Agostino RB, Kannel WB, Stepanians MN, et al.: Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol 1993, 71:82–87.
Muramatsu J, Kobayashi A, Hasegawa N, et al.: Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997, 130:179–182.
Antonicelli R, Onorato G, Pagelli P, et al.: Simvastatin in the treatment of hypercholesterolemia in elderly patients. Clin Ther 1990, 12:165–171.
Kool M, Lustermans F, Kragten H, et al.: Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995, 48:217–223.
Borghi C, Gaddi A, Ambrosioni E, et al.: Improved blood pressure control in hypertensive patients treated with statins. J Am Coll Cardiol 2001, 37(suppl A):233A-234A.
Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281–1286. This is the only published paper reporting the results of a doubleblind, crossover, randomized study done to establish the capacity of statins to reduce blood pressure in hypertensive men. It demonstrates the blood pressure-lowering efficacy of statins as well as their capacity to reduce pressor response to stress.
Tonolo G, Melis MG, Formato M, et al.: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000, 11:980–987. The authors report that the effects of statins on blood pressure control cannot be achieved with the use of cholestyramine.
Velussi M, Cernigoi AM, Tortul C, et al.: Atrovastatin for the management of type-2 diabetic patients with dyslipidemia. A mid-term (9-month) treatment experience. Diabetes Nutr Metab 1999, 12:407–412. This paper confirms that statins can reduce blood pressure in diabetic patients.
Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999, 83:1497–1499. This is the first published paper reporting a possible pharmacodynamic interaction between statins and antihypertensive drugs. The data reported in the study are limited to ACE inhibitors that could be considered a good solution for combining with statins.
Borghi C, Prandin MG, Costa FV, et al.: Use of statins and blood pressure control in hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000, 35:549–555. This paper demonstrates the importance of statin treatment for improving blood pressure control in treated hypertensive patients. The effect of statins is enhanced in patients treated with ACE inhibitors and calcium channel blockers, and is largely independent of the lipid-lowering activity.
Egashira K, Hirooka Y, Kai H, et al.: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519–2524.
O’Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126–1131.
Lewis TV, Cooper BA, Dart AM, et al.: Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. Br J Pharmacol 1998, 124:222–228.
Laufs U, La Fata V, Plutzky J, et al.: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129–1135. This report shows the capacity of statins to regulate the endothelial function acting through the activity of NO synthase. This mechanism might be involved in the blood pressure-lowering effect of statins.
Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999, 33:234–241.
Nickenig G, Baumer AT, Temur Y, et al.: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131–2134. The paper describes the capacity of high cholesterol levels and statins to modulate the expression of AT1 receptors in men. This effect of statins could be responsible for the changes in pressor reactivity to angiotensin II observed in patients with hypercholestrolemia before and after the treatment with statins. An active modulation of AT1 receptors may help to explain the blood pressure-lowering effect of statins.
Ide H, Fujiya S, Aanuma Y, et al.: Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990, 12(5):410–420.
Sartor G, Katzman P, Eizyk E, et al.: Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther 1995, 33:3–6.
Nazzaro P, Manzari M, Merlo M, et al.: Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999, 33:719–725.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borghi, C., Veronesi, M., Prandin, M.G. et al. Statins and blood pressure regulation. Current Science Inc 3, 281–288 (2001). https://doi.org/10.1007/s11906-001-0090-y
Issue Date:
DOI: https://doi.org/10.1007/s11906-001-0090-y